Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye

Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye

November 08, 2007

    SYDNEY, Australia, Nov. 8 /Xinhua-PRNewswire/ -- 

    In the Lancet, on Tuesday, November, 6th new results of
the Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) 2007 clinical trial have been published and
presented on the same date at a press conference held
during the AHA.

    - First lipid modifying agent shown to reduce the need
for treatment of
      the leading causes of blindness and deteriorating
vision in patients 
      with type 2 diabetes

    - Reduces need for laser treatment in patients with and
without known
      diabetic retinopathy

    - Significantly decreases progression of diabetic eye
disease

    If you are interested in knowing more about this
breaking news
and in getting additional information on the management of
microvascular
complications in type 2 diabetes, we are pleased to invite
you to visit "the
Field Study Investigators Website," where you will
have the opportunity to
login to the Webcast of the press conference.

    Please click below: http://www.thefieldtrial.org


    For more information, please contact:

     Beth Quinlivan
     University of Sydney
     Tel:    [phone]
     Mobile: [phone]
     Email: [e-mail]